Alternatives to Palforzia If You Can't Fill Your Prescription

Palforzia changed the peanut allergy treatment landscape when it received FDA approval in 2020. It was the first and only FDA-approved oral immunotherapy for peanut allergy — a true milestone for the millions of children and families managing this potentially life-threatening condition. But with Stallergenes Greer's voluntary discontinuation of Palforzia as of July 31, 2026, many patients and families are urgently searching for what comes next.

The good news: you have options. None of them are exact replacements, and each comes with its own considerations, but the peanut allergy treatment landscape does not end with Palforzia. Here is a comprehensive look at what alternatives exist.

Important: Do Not Stop Palforzia Abruptly

Before diving into alternatives, a critical safety note: if your child is currently on Palforzia, do not stop treatment without consulting your allergist. Abrupt discontinuation can reverse the desensitization your child has achieved, potentially restoring full sensitivity to peanut allergens. Work with your allergist to plan a safe transition to whichever alternative is most appropriate.

Alternative 1: Office-Based Peanut Oral Immunotherapy (OIT)

The most direct alternative to Palforzia is office-based peanut OIT — also called "real-food" or "grocery store" OIT. Many allergists who were already performing peanut OIT before Palforzia's arrival, or who found Palforzia's REMS requirements too burdensome, offer OIT using non-pharmaceutical peanut flour or whole peanuts purchased from the grocery store.

This approach uses the same fundamental principle as Palforzia: gradually escalating doses of peanut protein to build tolerance. The key differences are:

Not FDA-approved: Office-based OIT uses off-label products; insurance coverage is often inconsistent.

Less standardized: Dosing protocols vary by practice; Palforzia's precisely measured capsules offered standardization that grocery-store peanuts cannot perfectly replicate.

Lower cost: Office-based OIT typically costs far less than Palforzia's $890/month list price, often just a few hundred dollars for supplies and visits.

Growing availability: More allergists are offering it as Palforzia exits the market.

If you're transitioning from Palforzia, ask your allergist whether they can continue your child's protocol using measured peanut flour or a similar office-based approach at the same dose level your child has reached.

Alternative 2: Omalizumab (Xolair) — FDA-Approved for Food Allergy

In February 2024, the FDA approved omalizumab (Xolair; Genentech/Novartis) for the reduction of allergic reactions from accidental food exposure — including peanut — in children and adults ages 1 and older. This was a landmark decision that provides a meaningful alternative for patients who cannot or will not undergo OIT.

How Xolair differs from Palforzia:

Mechanism: Xolair is an anti-IgE antibody that blocks the IgE molecules responsible for triggering allergic reactions. It does not desensitize the immune system to peanut — it intercepts the allergic response.

Coverage: Xolair covers multiple food allergens simultaneously, not just peanut. For kids allergic to peanut plus other foods, this is a significant advantage.

Administration: Injected every 2-4 weeks in a clinical setting — no daily at-home dosing required.

Limitation: Unlike OIT, Xolair's protection is not expected to last long-term once the medication is stopped. Palforzia aimed to train the immune system; Xolair manages symptoms while you're taking it.

Cost: Xolair is expensive (roughly $2,900-$5,000/month without insurance), but it is covered by many insurance plans for its established indications, and prior authorization pathways exist.

Alternative 3: Strict Peanut Avoidance + Epinephrine Auto-Injector

For families who choose not to pursue OIT or Xolair, or for whom those options are not appropriate, strict peanut avoidance combined with carrying an epinephrine auto-injector (EpiPen, Auvi-Q, or generic) remains a valid management strategy. While it does not reduce sensitivity or train the immune system, it remains the standard-of-care baseline that has protected peanut-allergic individuals for decades. An anaphylaxis emergency action plan should be maintained and shared with schools, caregivers, and family members.

38,418+ patients found their medications in stock

38K+

Find Palforzia 3 mg In Stock Today →

Alternative 4: Investigational Treatments (Not Yet Approved)

Several promising treatments are in clinical trials but not yet FDA-approved:

Viaskin Peanut (DBV Technologies): An epicutaneous immunotherapy (EPIT) patch that delivers peanut protein through the skin. It avoids the systemic reactions of OIT. Still in trials.

Sublingual immunotherapy (SLIT): Peanut protein placed under the tongue in small doses. Studies show promise with fewer side effects than OIT; not yet FDA-approved.

Ozureprubart (investigational): An anti-IgE therapy by RAPT Therapeutics (acquired by GSK) similar to Xolair but designed for less frequent dosing (every 12 weeks). In early clinical trials.

How to Find These Alternatives Near You

Your first step is always to talk to your allergist. If you need help finding an allergist who offers office-based OIT or Xolair, check AAAAI's provider directory or ask for a referral. If you're still trying to locate remaining Palforzia supply while exploring alternatives, medfinder can search pharmacies near you to check current availability. Whatever path you choose, don't navigate this transition alone — your allergist is your most important resource.

Skip the calls, skip the stress.

Find Palforzia 3 mg In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Summary: Palforzia Alternatives at a Glance

Office-based peanut OIT: Most similar to Palforzia; not FDA-approved; lower cost; growing availability.

Omalizumab (Xolair): FDA-approved for food allergy; covers multiple allergens; injection every 2-4 weeks; protection stops if drug is stopped.

Strict avoidance + epinephrine: Always valid; no desensitization; essential baseline for all peanut-allergic patients regardless of other treatment.

Investigational treatments: Not yet approved; ask allergist about clinical trial eligibility.